News : Altavo concludes Series A for the development of its Artificial Voice

Altavo’s Arti­fi­cial Voice is a medi­cal device desi­gned to help voice­l­ess peo­ple, for exam­ple after laryn­gec­tomy or during mecha­ni­cal ven­ti­la­tion, regain their own, natu­ral sound­ing voice. The pro­prie­tary “silent speech” tech­no­logy, which has been deve­lo­ped in col­la­bo­ra­tion with Tech­ni­cal Uni­ver­sity Dres­den, is based on non-inva­sive radar sens­ing and the latest neu­ral net architectures.

Inves­tors in the cur­rent sign­fi­cantly over­sub­scri­bed round are, in addi­tion to the lead inves­tor OCCIDENT from Munich, Nova­lis Bio­tech (Ghent, Bel­gium), Betei­li­gungs­ma­nage­ment Thü­rin­gen, and others. In addi­tion, almost all seed inves­tors from the first finan­cing round in Decem­ber 2021 are par­ti­ci­pa­ting with a fol­low-on invest­ment, among them TGFS Tech­no­lo­gie­grün­der­fonds Sach­sen, High-Tech Grün­der­fonds (HTGF), Saxo­nia Sys­tems Hol­ding and TUDAG TU Dres­den AG.

The cur­rent Series A will finance com­pany growth, pro­duct deve­lo­p­ment, the pivo­tal cli­ni­cal trial, and inter­na­tio­na­liza­tion. Altavo’s tech­no­logy not only pro­mi­ses to become a breakth­rough in the reha­bi­li­ta­tion of voice­l­ess peo­ple, but also opens up enti­rely new oppor­tu­ni­ties in silent com­mu­ni­ca­tion and human-machine interfaces.